Stockholders Equity (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
|---|
| Stockholders Equity [Abstract] |
|
| Schedule of Outstanding Warrants to Purchase Common Stock Issued To Stockholders |
As of September 30, 2023, the Company
had the following outstanding warrants to purchase Common Stock issued to stockholders:
| Warrant |
|
Issuance Date |
|
Expiration Date |
|
Exercise
Price Per
Share |
|
|
Number of
Shares of
Common
Stock
Underlying
Warrants |
|
| Private Placement Warrants |
|
IPO (December 13, 2018) |
|
December 13, 2023 |
|
|
11.50 |
|
|
|
2,900,000 |
|
| Public Warrants |
|
IPO (December 13, 2018) |
|
October 28, 2024 |
|
|
11.50 |
|
|
|
3,500,000 |
|
| 2021 Registered Direct Offering Warrants |
|
SPA (July 28, 2021) |
|
January 28, 2027 |
|
|
5.00 |
|
|
|
2,812,501 |
|
| Pre-Funded Warrants |
|
February 27, 2023 |
|
- |
|
|
0.001 |
|
|
|
2,776,428 |
|
| Pre-Funded Warrants |
|
May 4, 2023 |
|
- |
|
|
0.001 |
|
|
|
11,834,286 |
|
| |
|
|
|
|
|
|
|
|
|
|
23,823,215 |
|
|
| Schedule of Black-Scholes Option-Pricing Model |
The fair value of each option was estimated
as of the date of grant or reporting period using the Black-Scholes option-pricing model, using the following assumptions:
| |
|
Nine Months Ended
September 30, |
|
| |
|
2023 |
|
|
2022 |
|
| Underlying value of Common Stock ($) |
|
|
0.36-0.40 |
|
|
|
0.37-1.41 |
|
| Exercise price ($) |
|
|
0.36-0.40 |
|
|
|
0.37-1.41 |
|
| Expected volatility (%) |
|
|
94.3-96.6 |
|
|
|
85.3-88.4 |
|
| Expected terms of the option (years) |
|
|
6.11 |
|
|
|
5.31-6.11 |
|
| Risk-free interest rate (%) |
|
|
4.21-4.44 |
|
|
|
2.50-4.05 |
|
|
| Schedule of Summary of Options Granted to Purchase |
A
summary of options granted to purchase the Company’s Common Stock under the Company’s share option plans is as follows:
| |
|
For the Nine Months Ended
September 30, 2023 |
|
| |
|
Number of
Options |
|
|
Weighted
Average
Exercise Price |
|
|
Aggregate
Intrinsic
Value |
|
| Outstanding at the beginning of period |
|
|
4,769,441 |
|
|
$ |
2.93 |
|
|
$ |
40 |
|
| Granted |
|
|
1,625,000 |
|
|
$ |
0.40 |
|
|
|
|
|
| Forfeited |
|
|
(329,860 |
) |
|
$ |
2.32 |
|
|
|
|
|
| Expired |
|
|
(154,245 |
) |
|
$ |
4.69 |
|
|
|
|
|
| Exercised |
|
|
- |
|
|
$ |
- |
|
|
|
|
|
| Outstanding at the end of period |
|
|
5,910,336 |
|
|
$ |
2.22 |
|
|
$ |
76 |
|
| Exercisable at the end of period |
|
|
3,234,658 |
|
|
$ |
3.02 |
|
|
|
|
|
| Weighted average remaining contractual life of outstanding options – years as of September 30, 2023 |
|
|
7.03 |
|
|
|
|
|
|
|
|
|
|
| Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock |
As of September 30, 2023, the Company
had the following outstanding compensation related warrants to purchase Common Stock:
| Warrant |
|
Issuance
Date |
|
Expiration
Date |
|
|
Exercise
Price
Per Share |
|
|
Number of
Shares of
Common Stock
Underlying
Warrants |
|
| Private Warrants issued to scientific founders (see below) |
|
November 27, 2017 |
|
|
- |
|
|
|
- |
|
|
|
2,974 |
|
|
| Schedule of Stock-Based Payment Expenses |
The
following table sets forth the total stock-based payment expenses resulting from options granted, included in the statements of operations:
| |
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
| |
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
| Research and development expenses, net |
|
|
31 |
|
|
|
104 |
|
|
|
202 |
|
|
|
352 |
|
| General and administrative |
|
|
164 |
|
|
|
259 |
|
|
|
439 |
|
|
|
810 |
|
| |
|
|
195 |
|
|
|
363 |
|
|
|
641 |
|
|
|
1,162 |
|
|